Correlations between the Expression Levels of Micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the Clinicopathologic Parameters in Papillary Thyroid Cancers

Abstract

Context:

It has been shown that miRNA 221, 222 and 146b are increasingly expressed while p27^Kip1 is suppressed in papillary thyroid cancer (PTC).

Objective:

We investigated the association between the disease recurrence risk and the expression of miRNA 221, 222, 146b and p27^Kip1 protein mRNA in these tumors. We also measured the changes in miRNAs in the presence of Hashimoto’s thyroiditis (HT).

Methods:

We examined formalin fixed tissue samples obtained from 77 patients. 11 out of 77 samples were identified as well differentiated tumor with uncertain malignant potential (WDT-UMP), 46 were PTC and 20 were normal thyroid tissue.

Results:

Data analysis revealed that the higher risk of recurrence was associated with the higher miRNA expression levels in thyroid cancers. Higher expression levels of miRNA 146b, 221 and 222 were detected in thyroid cancer patients presenting with capsule invasion, vascular invasion or lymph node metastasis, when compared to the patients lacking these features. Furthermore miRNA expression levels were found to be significantly elevated in patients with distant metastases. A negative correlation was found between the p27^Kip1 protein mRNA level and the expression levels of miRNA 221, 222 and 146b. While the expression levels of miRNA 221, 222 and 146b were found to be higher in the cases of WDT-UMP comparing to normal thyroid tissue, the p27Kip1 protein mRNA expression level was lower. No difference was found between the patients with HT and without HT regarding miRNAs expression levels.

Conclusions:

The expression levels of miRNA 221, 222 and 146b were found to be increased in cases of thyroid cancer with a high risk of recurrence. It is important to understand that these molecular changes such as miRNA expression may eventually be used to predict risk of recurrence.

Key words

MiRNAs - thyroid cancer - Hashimoto’s thyroiditis

• References

• 1 Tai P, Mould RF, Prysyazhnyuk AY et al. Descriptive epidemiology of thyroid carcinoma. Current Oncology 2003; 10: 54-65
• 2 Hofman V, Lassalle S, Bonnetaud C et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch 2009; 455: 21-33
• 3 Chou CK, Chen RF, Chou FF et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation. Thyroid 2010; 20: 489-494
• 4 Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev 2009; 28: 369-378
• 5 Eckstein F. Small non-coding RNAs as magic bullets. Trends Biochem Sci 2005; 30: 445-452
• 6 Mattick JS, Makunin IV. Small regulatory RNAs inmammals. Hum Mol Genet 2005; 14: R121-R132
• 7 Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355
• 8 Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529
• 9 Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation inhuman breast cancer. Cancer Res 2005; 65: 7065-7070
• 10 Metzler M, Wilda M, Busch K et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004; 39: 167-169
• 11 Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033
• 12 He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102: 19075-19080
• 13 Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association withshortened postoperative survival. Cancer Res 2004; 64: 3753-3756
• 14 Hayashita Y, Osada H, Tatematsu Y et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-9632
• 15 Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545
• 16 Visone R, Russo L, Pallante P et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007; 14: 791-798
• 17 Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838
• 18 Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760
• 19 Calin GA, Ferracin M, Cimmino A et al. microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801
• 20 Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627-3632
• 21 Gao Y, Wang C, Shan Z et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J 2010; 57: 81-86
• 22 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
• 23 Pallante P, Visone R, Croce CM et al. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer 2010; 17: F91-F104
• 24 Taganov KD, Boldin MP, Chang KJ et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innateimmune responses. PNAS 2006; 103: 12481-12486
• 25 Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 2006; 13: 497-508
• 26 Chen YT, Kitabayashi N, Zhou XK et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008; 21: 1139-1146
• 27 Sheu SY, Grabellus F, Schwertheim S et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. British Journal of Cancer 2010; 102: 376-382
• 28 Karube Y, Tanaka H, Osada H et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111-115
• 29 Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005; 90: 5723-5729
• 30 Fero ML, Rivkin M, Tasch M et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996; 85: 733-744
• 31 Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. Journal of Cell Physiology 2000; 183: 10-17
• 32 Cunha LL, Ferreira RC, Marcello MA et al. Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. J Thyroid Res 2011; 17: 2011 387062
• 33 Papotti M, Rodriguez J, De Pompa R et al. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumours with follicular architecture of uncertain malignant potential. Mod Pathol 2005; 18: 541-546
• 34 Scognamiglio T, Hyjek E, Kao J et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006; 126: 700-708
• 35 Fontaine JF, Mirebeau-Prunier D, Franc B et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene 2008; 27: 2228-2236